Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Fisher, Nanogen, PerkinElmer, Lumera, Pittcon

Beckman Coulter Says Q2 Revenues Miss Expectations
Revenues dropped in the second quarter for Beckman Coulter as sales in the Far East and in life science markets fell below expectations, the company said this week.
Beckman reported revenues of $616.3 million for the quarter, short of the $620 million to $645 million forecast by the company on May 3. During the second quarter of 2005, Beckman Coulter posted revenues of $618.8 million.
The company reported a net income of $44.6 million, down from $55.2 million a year ago. R&D spending totaled $75.1 million, up from $50.1 million a year ago. As of June 30, Beckman Coulter had $59.4 million in cash and cash equivalents.

Fisher, Nanogen to Share IP, Technology to Develop Diagnostics
Nanogen and Fisher Scientific International have reached an agreement to share technology and patent rights that will be used to develop, manufacture, and market new molecular diagnostic products. The agreement expands on Fisher’s equity investment in Nanogen reached in March.
Nanogen and Athena Diagnostics, a wholly owned subsidiary of Fisher, have also agreed to develop, manufacture, and market products based on Athena’s proprietary biomarkers for research and in vitro use.
Under the agreement, Fisher may provide up to $10 million in 2007 and 2008 for research and development in infectious diseases and molecular diagnostic tests mutually agreed upon.

Life and Analytical Sciences Liven PerkinElmer Q2 Rev Growth
PerkinElmer announced sales of $337 million in the second quarter ended July 2, a 2-percent jump from $368 million in the year-ago period fueled in part by a 3-percent jump in revenue in its Life and Analytical Sciences division.
For the quarter, sales in the division totaled $278.5 million, up from $270.8 million during the second quarter of 2005.
The company posted earnings of $24.5 million, a 15-percent drop from $28.9 million recorded during the year-ago period. 2006 Q2 results include intangibles amortization of $7.8 million and stock expenses of $2.1 million.  
PerkinElmer spent $25 million on R&D for the quarter, up from $22 million year over year. The company had cash and cash equivalents of $323.8 million as of the end of the quarter.

Bioscience Providing Light to Lumera?
Lumera CEO Tom Mino this week suggested the company could see revenue growth in its bioscience products as a result of the installation of the company’s ProteomicProcessor Biosensors.
Mino said three of the biosensors were installed during the quarter ended June 30, leading him to pronounce, “…we believe [this] puts us in a good position for achieving bioscience product revenue growth late this year.”
For the quarter, Lumera, a nanotechnology company, posted revenues of $665,000, a 91-percent increase from $348,000 a year ago. The company posted a net loss of $3.2 million, compared to $2.9 million a year ago. R&D for the quarter totaled $1.7 million. The company had $4.8 million in cash and cash equivalents.

Pittcon Perks Up Web site
The Pittsburgh Conference has redesigned its Web site for Pittcon 2007 enabling direct access to information about the conference and expo. Among the improvements to the site is the addition of an international travel section, organizers said in a press release.

Pittcon is scheduled for Chicago from Feb. 25 to March 2.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.